Overview
- Genentech exercised the collaboration’s first validated‑target option and triggered a $3 million milestone payment to Recursion as the target is advanced into a joint early small‑molecule discovery program.
- Recursion says the target came from its whole‑genome CRISPR knockout neuronal map built from massively scaled iPSC production and tens of millions of cellular images analyzed by its AI platform.
- Recursion will lead chemistry‑led hit generation and optimization for the program while Genentech supports downstream discovery work under the multi‑program collaboration.
- Recursion’s internal pipeline is progressing in parallel with REC‑7735 receiving IND clearance and a Phase 1/2 study planned to start in the second half of 2026 and REC‑4881 continuing development for FAP with FDA orphan and fast‑track designations and new Phase 2 data due in November 2026.
- The partnership has delivered $216 million to Recursion so far, can support up to about 40 small‑molecule programs with further milestones and royalties, and the company reported $556.8 million in cash with a runway into early 2028 under current plans.